By Business Wire, October 15, 2013, 09:15:00 AM EDT
- First clinical data to be reported for SAR566658, further expanding
the extensive body of data reported with ImmunoGen's maytansinoid
antibody-drug conjugate (ADC) technology.
- Presentations on new ADC technologies, including a new class of
payload agents, highlight ImmunoGen's continuing leadership in
advancing this high potential field.
WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (NASDAQ:IMGN), a biotechnology company that develops novel
anticancer therapeutics using its ADC technology, today announced the
Company-related poster presentations accepted for the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics
meeting to be held October 19-23, 2013 in Boston, MA.
The first clinical data with SAR566658 are to be reported. This ADC is a
potential new treatment for ovarian, pancreatic, breast and other
CA6-positive cancers in development by Sanofi through a collaboration
with the Company. Additionally, ImmunoGen scientists will report on the
Company's new platform of DNA-acting cytotoxic agents for use in ADCs as
well as on an additional linker ImmunoGen has added to its already
extensive technology portfolio.
On Sunday, Oct. 20, the first SAR566658 clinical data are scheduled to
be presented from 12:30-3:00 pm and 6:30-7:30 pm ET.
"A phase I first-in-human study of SAR566658, an
anti-CA-6-antibody-drug conjugate in patients with CA6-positive
advanced solid tumors" (Poster Session A, Abstract #A73).
On Tuesday, Oct. 22, 12:30-3:00pm ET, three posters on ImmunoGen's
expanding ADC technology portfolio are scheduled to be presented:
"New Class of DNA-alkylating agents with a suitable tolerability
profile created for use in antibody-drug conjugates (ADCs)" (Poster
Session C, Abstract #C160).
"Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents
display potent antigen-specific activity against hematologic and solid
tumor xenograft models" (Poster Session C, Abstract #C162).
"New tri-glycl peptide linker offers advantages for maytansinoid
antibody-drug conjugates (ADCs)" (Poster Session C, Abstract #C164).
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses a tumor-targeting engineered antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells. The most advanced compound with ImmunoGen's ADC technology
is Roche's Kadcyla®, which is marketed in the US by Genentech
and is also gaining approvals internationally. ImmunoGen has four wholly
owned clinical-stage product candidates, with additional compounds in
the clinic through its partnerships with Amgen, Bayer HealthCare,
Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a
member of the Roche Group.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products
and new anticancer technologies. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June
30, 2013 and other reports filed with the Securities and Exchange
Source: ImmunoGen, Inc.